14/10/2026 ImmunityBio secures US FDA expansion for ANKTIVA in BCG-Unresponsive Papillary Bladder Cancer Tab-cel BLA resubmission accepted by US FDA for EBV+ PTLD; PDUFA date set for March 2027 ImmunityBio secures US FDA expansion for ANKTIVA in BCG-Unresponsive Papillary Bladder Cancer (Ref) The US FDA expanded the approval of ANKTIVA® (nogapendekin alfa inbakicept-pmln; IL-15 receptor agonist) in combination with BCG to include patients with BCG-unresponsive non-muscle-inva